The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions

Medtronic Endovascular196 enrolled

Overview

To evaluate the safety and efficacy of the Complete SE SFA Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).

The Complete Self-Expanding (SE) SFA Stent is designed to be a permanent implant. It is cut from a nickel titanium alloy (Nitinol) tube and consists of a series of segments each connected to the next in a unique pattern to allow for flexibility and vessel conformability. Each segment consists of two struts and a crown (Figure 1). It is designed to produce optimal luminal diameter and increased scaffolding, and to maintain luminal patency.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

196

Conditions

Peripheral Vascular Disease

Interventions

Complete SE Vascular Stent SystemDEVICE

Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Rutherford 2-4, with an occlusion or de novo and/or restenotic SFA/PPA lesion ≥50% and ankle-brachial index/toe-brachial index (ABI/TBI) \<0.90/0.80. 2. Target lesion located at least 1 cm distal to the take-off of the profunda femoris artery and at least 3 cm proximal to the highest point of the cortical margin of the femur; 3. Target vessel reference diameter is ≥4.0 mm and ≤7.0 mm (visual estimate); 4. Target lesion length is ≥4.0 cm and ≤14.0 cm (visual estimate); 5. Adequate distal run-off to the ankle in the target limb (defined as having at least one patent calf vessel \<50% stenosed; 6. Life expectancy \>12 months. Exclusion Criteria: 7. Women who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment; 8. Any condition that precludes safe access with percutaneous transluminal angioplasty (PTA) devices, such as: excessive peripheral artery disease, unresolved fresh thrombus in the target lesion/vessel, or a target lesion/vessel that is excessively tortuous or calcified; 9. Lesions in contralateral SFA/PPA that require intervention during the index procedure, or within 30 days before or after the index procedure; 10. Previous treatment to the target lesion within the 3 months prior to enrollment; previous femoropopliteal bypass in target vessel; previous stenting of the target lesion; 11. Target lesion located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion; 12. Target lesion requires treatment other than standard PTA prior to stent placement (i.e., no other devices or procedures such as cutting balloons and laser atherectomy are permitted to be used during the index procedure); 13. History of bleeding diatheses or coagulopathy or will refuse blood transfusions; 14. Known impaired renal function, defined as creatinine \>2.5 mg/dl; 15. Known platelet count \<80,000 cells/mm3 or \>700,000 cells/mm3; 16. Known white blood cell (WBC) of \<3,000 cells/mm3; 17. Participation in another investigational device or drug study and has not completed the primary endpoint(s) or which clinically interferes with the Complete SE SFA Study endpoints, or previously enrolled in the Complete SE SFA Study.

Locations (4)

Washington Hospital

Fremont, California, United States

N. Florida Regional Medical Center

Gainesville, Florida, United States

Munroe Regional Medical Center

Ocala, Florida, United States

AnMed Health

Anderson, South Carolina, United States

Outcomes

Primary Outcomes

Major Adverse Event (MAE) Rate

Major Adverse Events (MAE) defined as device and/or procedure related death (or any death occurring post-procedure through Day 30), target limb loss and target lesion or target vessel revascularization.

Time frame: 12 Months

Primary Patency Rate

Primary patency defined as uninterrupted patency with no procedures performed on or at the margins of the treated segment, with no restenosis ≥ 50% as documented by peak systolic velocity ratio ≥2.0 as assessed by duplex ultrasound (DUS).

Time frame: 12 Months

Secondary Outcomes

Major Adverse Event (MAE) Rate

Time frame: 30 days

Major Adverse Event (MAE) Rate

Time frame: 6 Months

Device Success

The outcome is based on the angiographic evidence of \<30% final residual stenosis of the target lesion using only the assigned device.

Time frame: At time of deployment to the end of the treatment procedure (removal of vascular sheath from the patient).

Lesion Success

The outcome is based on the angiographic evidence of \<30% final residual stenosis of the target lesion using either the Complete SE SFA Stent System or other standard percutaneous devices.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.